03 August,2020 11:48 AM IST | New Delhi | IANS
This image has been used for representational purposes only
The Drugs Controller General of India (DCGI) has given approval to Pune's Serum Institute of India (SII) to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.
The SII received approval by the India's top drug regulator on Sunday after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
In a statement, the Health Ministry said, "Drugs Controller General of India has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India."
The institute had submitted a application seeking permission for conducting the trial in July last week.
ALSO READ
BCCI channels 'lockdown-style' secrecy for Team India in Perth
Smog creating lockdown-like situation in Pakistan
Consumer forum orders Rs 1 lakh refund to man who booked wedding hall during Covid-19 lockdown
Police swarm Georgia high school after it's placed on lockdown as students evacuated to stadium
Why more men are turning to crocheting
The vaccine candidate is in the midst of Phase II and III clinical trials in the UK, Phase III trials in Brazil, and Phase I and II clinical trials in South Africa.
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
